Literature DB >> 16102127

Homocysteine and tissue factor pathway inhibitor levels in patients with Fabry's disease.

S Fedi, F Gensini, A M Gori, R Abbate, W Borsini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16102127     DOI： 10.1111/j.1538-7836.2005.01470.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  3 in total

1.  Homocysteine and erythrocyte sedimentation rate correlate with cerebrovascular disease in fabry disease.

Authors:  R Cheung; D O Sillence; M C Tchan
Journal:  JIMD Rep       Date:  2012-02-01

Review 2.  Can we use statins to prevent stroke in Fabry disease?

Authors:  J M Politei
Journal:  J Inherit Metab Dis       Date:  2009-06-02       Impact factor: 4.982

3.  Evaluation of oxidative stress markers and cardiovascular risk factors in Fabry Disease patients.

Authors:  Karen B Müller; Luciano C Galdieri; Vanessa G Pereira; Ana M Martins; Vânia D'Almeida
Journal:  Genet Mol Biol       Date:  2012-05-17       Impact factor: 1.771
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.